SEC Comment Letter for CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869) (CAPR) — May 14, 2020
CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869)
Date: May 14, 2020 · CIK: 0001133869 · Accession: 0000000000-20-004293
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238088
Letter
United States securities and exchange commission logo May 14, 2020 Linda Marbán, Ph.D. Chief Executive Officer Capricor Therapeutics, Inc. 8840 Wilshire Blvd., 2nd Floor Beverly Hills, CA 90211 Re:Capricor Therapeutics, Inc. Registration Statement on Form S-3 Filed May 7, 2020 File No. 333-238088 Dear Ms. Marbán: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert R. Carlson, Esq.
Show Raw Text
United States securities and exchange commission logo
May 14, 2020
Linda Marbán, Ph.D.
Chief Executive Officer
Capricor Therapeutics, Inc.
8840 Wilshire Blvd., 2nd Floor
Beverly Hills, CA 90211
Re:Capricor Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 7, 2020
File No. 333-238088
Dear Ms. Marbán:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert R. Carlson, Esq.